Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.51 |
| ▸ | GRAMD1A | Q96CP6 | 5/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129461 | 0.96 | CRBN (0.56) | CRBNDDB1GRAMD1ATNFIL1B | |
| SCHEMBL24819464 | 0.95 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL30732167 | 0.95 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL26925221 | 0.95 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL30738833 | 0.95 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL30731968 | 0.92 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL26924761 | 0.92 | CRBN (0.54) | CRBNDDB1BTKGRAMD1ATNF | |
| SCHEMBL20294709 | 0.88 | CRBN (0.59) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL31129437 | 0.86 | IKZF1 (0.49) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL26814088 | 0.86 | CRBN (0.58) | CRBNDDB1BTKTNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | CRBN 1/4885DDB1 1314/4885BTK 1883/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | CRBN 2/4885DDB1 1105/4885BTK 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.